TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics (NASDAQ: TGTX) will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, at the Marriott Marquis, New York City. Michael S. Weiss, Chairman and CEO, will conduct a fireside chat on June 5, 2024, at 1:30 PM ET. The event will be webcast live and accessible on TG Therapeutics' website.
The conference appearance aims to provide updates on the company's progress and strategies, potentially impacting investor perception and stock performance.
- TG Therapeutics' participation in a major healthcare conference enhances visibility and investor engagement.
- Michael S. Weiss, the CEO, leading the presentation could indicate strategic updates and insights into company progress.
- Live webcast availability broadens access for investors and stakeholders who cannot attend in person.
- The press release lacks specific updates on financial performance or clinical trial results, potentially leaving investors wanting more concrete information.
- Investor expectations might be high, and any perceived lack of substantial news or progress could negatively impact stock performance.
Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When will TG Therapeutics participate in the Jefferies Global Healthcare Conference?
Who will represent TG Therapeutics at the Jefferies Global Healthcare Conference?
What is the date and time of the TG Therapeutics fireside chat at the Jefferies Global Healthcare Conference?
Where can I watch the TG Therapeutics fireside chat?
What is the stock symbol for TG Therapeutics?
